Dynavax Technolo Stock Price, News & Analysis

Sensorion (Euronext Paris: ALSEN) has appointed Scott D. Myers as Chairman of its Board of Directors, succeeding Edwin Moses who is stepping down on December 19. Myers, currently Chairman at Dynavax Technologies (NASDAQ: DVAX) and Harpoon Therapeutics (NASDAQ: HARP), brings nearly 30 years of experience in the pharmaceutical sector. His leadership is expected to enhance Sensorion's clinical development and international presence, particularly as the company focuses on its innovative therapies for hearing loss disorders.

Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Elaine Sun to its Board of Directors. Ms. Sun, who brings over 20 years of experience in life sciences and investment banking, has previously held significant roles at Halozyme and SutroVax. CEO Ryan Spencer expressed confidence in her expertise to enhance Dynavax's strategic direction, particularly in expanding HEPLISAV-B market share and advancing their CpG 1018 adjuvant development. The announcement highlights Dynavax's commitment to innovative vaccine solutions against infectious diseases.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of nonstatutory stock options for 58,500 shares to 5 new employees on December 1, 2021. The options have an exercise price of $15.11 per share, aligning with the closing stock price on that date. Each option has a 7-year term and will vest over three years. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an inducement to employment under the 2021 Inducement Award Plan.

Dynavax Technologies Corporation (NASDAQ: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on November 30 at 2:40 p.m. E.T. The live audio webcast can be accessed via the company's Investors section. A replay will be available for 30 days post-event. Dynavax is known for its HEPLISAV-B® vaccine approved for hepatitis B prevention and is advancing its CpG 1018 adjuvant for various vaccines.

Dynavax Technologies Corporation (Nasdaq: DVAX) reported strong financial results for Q3 2021, achieving total revenue of $108.3 million, driven by substantial growth in its HEPLISAV-B vaccine and CpG 1018 adjuvant. Revenue for HEPLISAV-B rose to $22.7 million, up from $11.6 million year-over-year, with market share increasing to 33.5%. CpG 1018 revenue soared to $84.3 million, up from $1.7 million in Q3 2020. Net loss widened to $28.4 million, reflecting a significant non-cash loss related to warrant liability. The company ended the quarter with $414.2 million in cash and equivalents.

On November 2, 2021, Dynavax Technologies Corporation (DVAX) announced the granting of nonstatutory stock options for 5,000 shares to a newly hired employee. The options, granted at an exercise price of $20.56 per share, equal the stock's closing price on the grant date. Each option has a 7-year term and vests over three years. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan aimed at incentivizing new hires.

Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Scott Myers as a new member and Chairman of its Board of Directors, succeeding Dr. Andrew Hack. Myers brings nearly three decades of experience in the pharmaceutical and medical technology sectors. Under his leadership, Dynavax aims to enhance growth, focusing on its key products: HEPLISAV-B and CpG 1018. Dr. Hack remains on the board, providing continued guidance. This leadership change is expected to strengthen the company's strategic direction in vaccine development.

Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2021 financial results on November 4, 2021, after market close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET. Interested parties can access the webcast via the company’s investors' section. Dynavax is known for developing HEPLISAV-B, a hepatitis B vaccine, and is advancing its CpG 1018 adjuvant through research collaborations targeting vaccines for various diseases.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options for 115,000 shares to a new employee, effective October 18, 2021. The options have an exercise price of $17.14, aligned with the stock's closing price on the grant date. These options have a 7-year term and vest over three years, with one-third vesting after one year and the remainder in monthly installments. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and follows their 2021 Inducement Award Plan for new hires.